Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PTEN negative |
| Therapy | GSK2636771 |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PTEN negative | Advanced Solid Tumor | no benefit | GSK2636771 | Phase II | Actionable | In a Phase II trial (MATCH), GSK2636771 treatment did not meet the primary endpoint of objective response in patients with advanced solid tumors with PTEN protein loss (n=35), resulting in stable disease in 22% (7/35) of the patients, a median progression-free survival of 1.8 months, and a median overall survival of 5.9 months (PMID: 40865033; NCT02465060). | 40865033 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40865033) | PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P. | Full reference... |